Figure S11 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Soyoung Lee; Kyunghwan Kim; Hye‐Jin Jeong; Subin Choi; Himchan Cheng; Dayoung Kim; Soomin Heo; Jinhee Mun; Minjong Kim; Eunjin Lee; Yoon Ji Choi; Seon‐gyeong Lee; Eun A Lee; Yewon Jang; Kayeong Lim; Heon Seok Kim; Euihwan Jeong; Seung‐Jae Myung; Deok‐Beom Jung; Chang Sik Yu; In Ho Song; M. Ryan Corces; Joo H. Kang; Kyungjae Myung; Taejoon Kwon; Tae‐Eun Park; Jinmyoung Joo; Seung Woo Cho

doi:10.1158/0008-5472.29760209

Key Points

Main finding shows that using CRISPR/Cas9 and PARP inhibitors together enhances tumor suppression effects.
Key evidence includes two rounds of intratumoral injections demonstrating significant efficacy in the HCT-116 xenograft model.
The approach involved using RNP-loaded LNPs for targeted delivery of CRISPR/Cas9 to cancer cells.
Significance lies in developing precise treatments that could improve outcomes for patients with cancer.

Implication

Figure S11 demonstrates enhanced tumor suppression with intratumoral CRISPR/Cas9 and PARP inhibitors in a xenograft model, indicating improved cancer-targeting strategies.

Abstract

Figure S11 assesses the enhanced tumor suppression effects of two rounds of intratumoral injections with CRISPR/Cas9 RNP-loaded LNPs in an HCT-116 xenograft model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0274 https://doi.org/10.1158/0008-5472.29760209

View Full Paper

Ask AI

Bookmark

Share

Figure S11 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S11 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading